Literature DB >> 22359045

Development of a serum-free and heat-sterilizable medium and continuous high-density cell culture.

Y Minamoto1, K Ogawa, H Abe, Y Iochi, K Mitsugi.   

Abstract

We tried to establish a new serum-free and heat-sterilizable medium, based on our serum-free medium in which many lymphoblastoid cells and hybridoma could grow as well as in a conventional serum-containing medium.As is well-known, L-glutamine (L-Gln) is one of the most heat-labile but essential components for cell growth. As a substitute for L-Gln, dipeptide such as Gly-L-Gln or L-Ala-L-Gln, which was quite stable even after autoclaving, was found to be utilizable for mammalian cell growth. The L-Gln dipeptide-containing serum-free medium was quite stable in a solution even after storing at 37°C for 4 months. In the serum-free medium containing L-Ala-L-Gln, mouse hybridola could grow and produce more antibody than in RPMI 1640+10% FBS.It has been proved that BSA and transferrin, which are also heat-labile but essential for the growth of various cell lines, can be substituted by heat-stable alpha-cyclodextrin and cholesterol, and Fe-gluconate, respectively. Insulin has also proved to be heat stable in a solution of Fe-gluconate. We thus established a new serum-free medium, all the components of which could be heat-sterilizable.Moreover, by adding EGF and BSA but without the adhesion factor included in FBS, the serum-free medium was found to support a long-term serial culture of a human diploid fibroblast.Finally, with this auotoclavable serum-free medium in a perfusion culture apparatus, we were able to continuously cultivate a human lymphoblastoid cell line. The production rate of IgM was found to be markedly increased by feeding the serum-free medium enriched by glucose, bicarbonate, L-Cys, and approtinin. The cell density reached as high as 2×10(8)/ml in the serum-free medium. Although the working volume in the reactor was only 1 1, the rate of IgM production reached 480 mg/day.The new heat-sterilizable serum-free medium has several advantages, because L-Gln peptide is a heat-stable and available precursor of L-Gln.

Entities:  

Year:  1991        PMID: 22359045     DOI: 10.1007/BF00573879

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  11 in total

1.  Human B cell, T cell and null cell leukaemic cell lines derived from acute lymphoblastic leukaemias.

Authors:  I Miyoshi; S Hiraki; T Tsubota; I Kubonishi; Y Matsuda; T Nakayama; H Kishimoto; I Kimura; H Masuji
Journal:  Nature       Date:  1977-06-30       Impact factor: 49.962

2.  An autoclavable powdered culture medium for mammalian cells.

Authors:  I Yamane; Y Matsuya; K Jimbo
Journal:  Proc Soc Exp Biol Med       Date:  1968-01

3.  Serum-free cell culture: a unifying approach.

Authors:  D Barnes; G Sato
Journal:  Cell       Date:  1980-12       Impact factor: 41.582

4.  Spontaneous interferon production and growth of lymphoblastoid cells in serum-free medium.

Authors:  T Sato; Y Minamoto; I Yamane; T Kudo; T Tachibana
Journal:  Exp Cell Res       Date:  1982-03       Impact factor: 3.905

5.  Growth of hybridoma cells in serum-free medium: ethanolamine is an essential component.

Authors:  H Murakami; H Masui; G H Sato; N Sueoka; T P Chow; T Kano-Sueoka
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

6.  Primary culture of human diploid cells and its long-term transfer in a serum-free medium.

Authors:  I Yamane; M Kan; H Hoshi; Y Minamoto
Journal:  Exp Cell Res       Date:  1981-08       Impact factor: 3.905

7.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

8.  Large-scale rotating filter perfusion system for high-density growth of mammalian suspension cultures.

Authors:  W R Tolbert; J Feder; R C Kimes
Journal:  In Vitro       Date:  1981-10

9.  Development of a serum-free medium for growth of NS-1 mouse myeloma cells and its application to the isolation of NS-1 hybridomas.

Authors:  T Kawamoto; J D Sato; A Le; D B McClure; G H Sato
Journal:  Anal Biochem       Date:  1983-04-15       Impact factor: 3.365

10.  Microencapsulated islets as bioartificial endocrine pancreas.

Authors:  F Lim; A M Sun
Journal:  Science       Date:  1980-11-21       Impact factor: 47.728

View more
  6 in total

1.  A serum-free medium for hybridoma cell culture.

Authors:  Z Chen; Y Ke; Y Chen
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

2.  Massive culture of human liver cancer cells in a newly developed radial flow bioreactor system: ultrafine structure of functionally enhanced hepatocarcinoma cell lines.

Authors:  M Kawada; S Nagamori; H Aizaki; K Fukaya; M Niiya; T Matsuura; H Sujino; S Hasumura; H Yashida; S Mizutani; H Ikenaga
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-02       Impact factor: 2.416

3.  Effect of lipid supplements on the production and glycosylation of recombinant interferon-gamma expressed in CHO cells.

Authors:  N Jenkins; P Castro; S Menon; A Ison; A Bull
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

4.  Adaptation of mammalian cells to non-ammoniagenic media.

Authors:  M Butler; A Christie
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

5.  Characterization of yeastolate fractions that promote insect cell growth and recombinant protein production.

Authors:  Chun Fang Shen; Taira Kiyota; Barbara Jardin; Yasuo Konishi; Amine Kamen
Journal:  Cytotechnology       Date:  2007-06-05       Impact factor: 2.058

6.  Tracking dipeptides at work-uptake and intracellular fate in CHO culture.

Authors:  Andres Sánchez-Kopper; Max Becker; Jennifer Pfizenmaier; Christian Kessler; Andreas Karau; Ralf Takors
Journal:  AMB Express       Date:  2016-07-22       Impact factor: 3.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.